araag2/HINT huggingface dataset:
Clinical trial NCT00728793 (phase 1, status: completed)
Conditions: tumors
ICD codes: E88.3, R97.8, C49.A0, C49.A1, C49.A2, C49.A5, C49.A3
Drugs: cudc-101
SMILES: COC1=C(OCCCCCCC(=O)NO)C=C2C(NC3=CC=CC(=C3)C#C)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with advanced, refractory solid tumors and a histopathologically confirmed
             diagnosis

          -  Subjects must have no further standard of care options or have refused standard
             therapy

          -  Measurable or evaluable disease

          -  Age ≥ 18 years

          -  ECOG performance < 2

          -  Life expectancy ≥ 3 months

          -  If female, neither pregnant or lactating

          -  If of child bearing potential, must use adequate birth control

          -  Absolute neutrophil count ≥ 1,500/µL; platelets ≥ 100,000/µL;

          -  Creatinine ≤ 1.5x upper limit of normal (ULN) or calculated creatinine clearance ≥
             60mL/min/1.73m2

          -  Total bilirubin ≤ 1.5x ULN; AST/ALT ≤ 2.5x ULN. In subjects with documented liver
             metastases, the AST/ALT may be ≤ 5x ULN

          -  Prothrombin time ≤1.5x ULN, unless receiving therapeutic anticoagulation

          -  Serum magnesium and potassium within normal limits (may be supplement to achieve
             normal values)

          -  Subjects with brain metastases are eligible if controlled on a stable dose ≤ 10mg
             prednisone/day or its equivalent dose of steroids

          -  Able to render informed consent and to follow protocol requirements.

        Exclusion Criteria:

          -  Anticancer therapy within 4 weeks of study entry. Prostate cancer subjects on LHRH
             hormonal therapy may be enrolled and continue on this therapy.

          -  Use of investigational agent(s) within 30 days of study entry

          -  History of cardiac disease with a New York Heart Association (NYHA) Class II or
             greater congestive heart failure (CHF), myocardial infarction (MI) or unstable angina
             in the past 6 months prior to Day 1 of treatment, serious arrhythmias requiring
             medication for treatment.

          -  Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C.

          -  The following are permitted but should be used with caution and other suitable agents
             used if possible:

               -  Subjects receiving concomitant medications metabolized by CYP 3A4 and CYP 2D6

               -  CYP3A4 inducers

               -  CYP3A4 inhibitors

               -  Warfarin
Clinical trial NCT00207025 (phase 1, status: terminated)
Conditions: tumors
ICD codes: E88.3, R97.8, C49.A0, C49.A1, C49.A2, C49.A5, C49.A3
Drugs: bms-275183
SMILES: COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)C2=CC=CC=C2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(C)=C([C@@H](OC(C)=O)C1=O)C2(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Non-hematologic malignancy that has progressed or no standard therapy is known

          -  Four weeks from last chemotherapy or two weeks from last non-cytotoxic therapy

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1

          -  No more than 3 prior chemotherapy regimens in advanced/metastatic setting

          -  Absolute neutrophil count >=1,500/mm3 and platelets >=100,000/mm3

          -  Bilirubin <=1.5 x Upper Limit of Normal (ULN), Aspartate aminotransferase <=2.5 x ULN

          -  Serum creatinine <=1.5 x ULN

          -  Men and women >=18 years

          -  Women of Child Bearing Potential (WOCBP) must use adequate method of contraception
             throughout and up to 4 weeks after the study

        Exclusion Criteria:

          -  WOCBP and men not using adequate method of birth control

          -  WOCBP who are pregnant or breastfeeding

          -  Prior radiation >=25% of bone marrow containing skeleton

          -  Uncontrolled, significant, or active cardiovascular or pulmonary disease or infection
             or psychiatric disorder

          -  Neuropathy

          -  Active brain metastases

          -  Inability to swallow capsules

          -  History of gastrointestinal disease, surgery or malabsorption, or requiring use of a
             feeding tube

          -  Concurrent chemotherapy, hormonal therapy, immunotherapy, or radiotherapy
Clinical trial NCT01650727 (phase 1, status: completed)
Conditions: chronic lymphocytic leukemia, small lymphocytic lymphoma
ICD codes: C91.11, C91.12, C91.10, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: dinaciclib
SMILES: CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N1CCCC[C@H]1CCO
Eligibility criteria:

        Inclusion Criteria:

          -  Must have received at least one prior therapy that includes either

        fludarabine or equivalent nucleoside analogue or an alternative regimen

          -  Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic

        lymphoma (SLL)

          -  Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2

          -  Women of child-bearing potential who are sexually active, ,including both female
             subjects and the female sexual partners of male subjects, must agree to use a
             medically accepted method of contraception prior to enrollment, while receiving
             protocol-specified treatment, and for 12 months after stopping study treatment.

          -  Women of child-bearing potential who are not currently sexually active must

        agree to use a medically accepted method of contraception should they become

        sexually active while participating in the study.

          -  Life expectancy ≥12 weeks

        Exclusion Criteria:

          -  Symptomatic brain metastases or primary central nervous system malignancy

          -  Treatment with any chemotherapy or biologic therapy within 4 weeks prior to enrollment

          -  Non-hematological toxicities from prior therapy

          -  Presence of any serious or uncontrolled infection defined as infection requiring
             hospital admission and/or parenteral antibiotics

          -  Known human immunodeficiency virus (HIV) infection or a known HIV-related

        malignancy

          -  Clinically active hepatitis B or C defined as disease that requires

        therapy

          -  Women who are breast-feeding, pregnant, or intend to become pregnant

          -  Prior allogeneic bone marrow transplant (auto hematopoietic stem cell

        transplantation [HSCT] is allowed if fully recovered)

          -  Prior malignancy, except for adequately treated basal cell or squamous cell skin
             cancer, in situ cervical cancer or other cancer from which the subject is

        considered by his or her physician to have a 2 year survival expectation

          -  Any investigational drugs within 4 weeks prior to the start of treatment

          -  Concurrently receiving treatment in any other clinical study

          -  Previously treated with a cyclin dependent kinase (CDK) inhibitor (e.g., dinaciclib or
             flavopiridol)

          -  Active autoimmune anemia or idiopathic thrombocytopenic purpura (ITP) unless

        stable, defined as being responsive to corticosteroids or other standard therapy
Clinical trial NCT00878657 (phase 1, status: terminated)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: gemcitabine hydrochloride
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Pathologically confirmed adenocarcinoma or poorly differentiated carcinoma of the
             pancreas, ampulla of Vater, or distal bile duct

               -  Locally advanced disease

               -  Medically inoperable, unresectable, or borderline resectable disease

                    -  No previously resected disease (i.e., status post-pancreaticoduodenotomy)

          -  No non-adenocarcinoma, adenosquamous carcinoma, islet cell carcinoma, cyst adenoma,
             cystadenocarcinoma, carcinoid tumor, or duodenal carcinoma

          -  No lesions in the tail of the pancreas and/or splenic artery/vein
             involvement/encasement

          -  No recurrent or metastatic (M1) disease

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 60-100%

          -  WBC > 3,000/μL

          -  Platelet count > 100,000/μL

          -  Bilirubin ≤ 2 mg/dL

          -  SGOT < 5 times upper limit of normal (ULN)

          -  Creatinine < 1.5 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Adequate oral nutrition (e.g., ≥ 1,500 calories/day, stable weight for ≥ 2 weeks, and
             ≤ 5% weight loss)

          -  No active malignancy within the past 3 years, except cervical carcinoma in situ or
             nonmelanoma skin cancer that has been removed

          -  No severe, active comorbidity, including any of the following:

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  the past 6 months

               -  Transmural myocardial infarction within the past 6 months

               -  Acute bacterial or fungal infection requiring IV antibiotics at the time of study
                  registration

               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
                  requiring hospitalization within the past month or precluding study therapy at
                  the time of study registration

               -  Active hepatitis, decompensated cirrhosis, or clinically significant liver
                  failure

               -  Other severe comorbid condition, as determined by the principal investigator

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior chemotherapy

          -  No prior radiotherapy to any upper abdominal site

          -  No concurrent prophylactic colony-stimulating factors during radiotherapy

          -  No concurrent warfarin

          -  No other concurrent chemotherapy, immunotherapy, hormonal cancer therapy,
             radiotherapy, surgery for cancer, or experimental therapy
Clinical trial NCT00368329 (phase 1, status: terminated)
Conditions: esophageal neoplasms, carcinoma, squamous cell, adenocarcinoma, esophageal cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10, C44.520, C44.92, C44.02, C44.321, C44.521, C44.82, C44.42, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: capecitabine (xeloda), [18-f] fluorodeoxyglucose (fdg), 5-fluorouracil (5-fu), carboplatin
SMILES: [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H], [H]C(=O)[C@H]([18F])[C@@H](O)[C@H](O)[C@H](O)CO, FC1=CNC(=O)NC1=O, N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    low accrual
  
Eligibility criteria:

        Inclusion Criteria:- Confirmed diagnosis of adenocarcinoma or squamous cell carcinoma of
        the esophagus by pathologist.

          -  Endoscopic ultrasound or CT evidence of tumor penetration through the esophageal wall
             or involvement of regional lymph nodes, without evidence of distant metastasis

          -  No prior chest radiation therapy

          -  No prior chemotherapy for esophageal cancer

          -  Age greater than 18 years

          -  No infections requiring antibiotic treatment

          -  Able to care for self

          -  Patients must have acceptable liver, kidney and bone marrow function.

          -  The effects of the chemotherapy drugs on the developing human fetus are unknown. Women
             of child-bearing potential and men must agree to use adequate contraception. Exclusion
             Criteria:- Patients receiving any other investigational agents

          -  Evidence of distant metastases

          -  Uncontrolled medical illness

          -  Any malignancy other than non-melanoma skin cancer or carcinoma in situ of the cervix.

          -  Pregnant and breastfeeding women are excluded.

          -  HIV-positive patients
Clinical trial NCT01184482 (phase 1, status: completed)
Conditions: colorectal cancer, lung cancer, head and neck cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: cetuximab and lapatinib
SMILES: CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  At least one measurable lesion by RECIST criteria

          -  A tumor lesion that can be readily biopsied using a core needle via clinical exam,
             ultrasound, CT, or fluoroscopic-guidance

          -  Over the age of 18 years and able to provide informed consent

          -  Patients must have progressed after standard therapy for metastatic/ recurrent disease
             including 5-FU containing regimens for patients with colorectal cancer, and
             platinum-containing regimens for patients with head and neck cancer and non-small cell
             lung cancer.

          -  Patients may have received cetuximab, panitumumab or erlotinib previously

          -  Adequate kidney, liver, and bone marrow function

          -  Life expectancy greater than 3 months

          -  ECOG performance status </= 2

          -  Normal left ventricular ejection fractions

        Exclusion Criteria:

          -  Chemotherapy or surgery within 4 weeks prior to treatment start

          -  Radiation treatment within 3 weeks prior to treatment start

          -  Prior therapy with lapatinib

          -  Untreated brain metastasis or neurologically unstable CNS metastases

          -  Any severe or uncontrolled medical condition or other condition that could affect
             participation in this study including unstable angina, serious uncontrolled cardiac
             arrhythmia, uncontrolled infection, or myocardial infarction </= 6 months prior to
             study entry

          -  Diarrhea > grade 1 at baseline

          -  Patients on a medication or herbal therapy known to inhibit CYP3A4

          -  Gastrointestinal tract disease resulting in the inability to take oral medication or a
             requirement for IV alimentation, prior surgical procedures affecting absorption or
             active peptic ulcer disease

          -  Ongoing ventricular cardiac dysrhythmias of grade >/= 2

          -  Subjects with a history of serious ventricular arrhythmia (ventricular tachycardia or
             ventricular fibrillation >= 3 beats in a row)

          -  Serious cardiac arrhythmia requiring medication

          -  QTc interval > 500 msec

          -  Female patients who are pregnant or breast feeding, or adults who are of reproductive
             potential and are unwilling to refrain from conceiving a child during study treatment

          -  Patients unwilling or unable to comply with the protocol or provide informed consent
Clinical trial NCT00241189 (phase 1/phase 2, status: completed)
Conditions: systemic sclerosis
ICD codes: M34.0, M34.89, M34.9, M34.82, M34.83, M34.81, M34.2
Drugs: rapamycin, methotrexate
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Satisfy American College of Rheumatology classification criteria for systemic
             sclerosis

          -  Have skin thickening proximal to the elbows and/or knees (diffuse scleroderma)

          -  Cutaneous involvement for less than 5 years from the onset of the first non-Raynaud's
             manifestation

        Exclusion Criteria:

          -  Severe intractable malabsorption

          -  Chronic debilitation from any underlying disease

          -  Off putative disease modifying therapies for one month prior to entry
Clinical trial NCT00281996 (phase 1, status: terminated)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: gemcitabine, imatinib mesylate
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
Reason stopped: 
    closed to accrual to allow enrollment on another more promising trial.
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed pancreatic cancer

               -  Locally advanced, metastatic, or recurrent disease

          -  Measurable or evaluable disease by physical exam, plain radiographs, CT scan, or MRI

          -  No brain metastases

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy of 12 weeks or greater

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST ≤ 2.5 times ULN (5 times ULN if liver metastases are present)

          -  No chronic liver disease (i.e., chronic active hepatitis or cirrhosis)

          -  Creatinine ≤ 2.0 mg/dL

          -  No chronic renal disease

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier-method contraception during and for ≥ 3
             months after completion of study treatment

          -  No other malignancy within the past 5 years except basal cell skin cancer or carcinoma
             in situ of the cervix

          -  No uncontrolled diabetes

          -  No active uncontrolled infection

          -  No other severe and/or uncontrolled medical disease

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

          -  No prior therapy for metastatic disease

               -  Prior fluorouracil as a radiosensitizer for adjuvant therapy after surgery or for
                  locally advanced disease is permitted if local disease has recurred or progressed
                  ≥ 3 months after completion of therapy or disease is present outside the
                  radiation field

          -  At least 2 weeks since prior major surgery

          -  No concurrent grapefruit or grapefruit juice
Clinical trial NCT00478634 (phase 1, status: completed)
Conditions: colorectal cancer, colorectal carcinoma, colorectal tumors, neoplasms, colorectal
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: rad001, cetuximab, irinotecan
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion criteria:

          -  Age ≥ 18 years old and ≤ 65 years old.

          -  Patients with metastatic CRC. Confirmation of CRC diagnosis by histological or
             cytological specimen from original resection of primary tumor.

          -  Patients who progressed despite prior therapy with FOLFOX (5FU and oxaliplatin) plus
             bevacizumab or XELOX (capecitabine and oxaliplatin) plus bevacizumab.

          -  Patients with at least one measurable lesion by RECIST as determined by Computer
             Tomography (CT) Scan, Magnetic Resonance Imaging (MRI) or physical examination.

          -  Patients with a WHO performance status of 0 or 1.

        Exclusion criteria:

          -  Patients with Gilbert's syndrome or any other syndrome associated with deficient
             glucoronidation of bilirubin.

          -  Patients who are homozygous for the UGT1A1*28 allele as determined by sequencing.

          -  Patients who have received previous irinotecan-based therapy.

          -  Prior treatment with an mTOR inhibitor.

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00658671 (phase 1, status: completed)
Conditions: advanced cancer
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: enmd-2076
SMILES: CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C)C2=CC(=CC=C12)[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have histologic proof of advanced cancer that has progressed after treatment and has
             no standard therapy that is curative or provides clinical benefit.

          -  Meet the modified RECIST Criteria or have disease that can be followed for clinical
             benefit.

          -  Are greater than or equal to 18 years of age.

          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN)

          -  Total bilirubin ≤ ULN

          -  Creatinine ≤ 1.5 x ULN

          -  Absolute neutrophil count ≥ 1500 cells/mm3

          -  Platelets ≥ 100,000/mm3

          -  Hemoglobin ≥ 9.0 g/dL

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Agree to use effective contraceptive methods prior to study entry, during study
             participation, and for at least 30 days after the last administration of study
             medication.

          -  Have the ability to understand the requirements of the study, provide written informed
             consent which includes authorization for release of protected health information,
             abide by the study restrictions, and agree to return for the required assessments.

        Exclusion Criteria:

          -  Women who are pregnant or nursing.

          -  Have received radiotherapy or chemotherapy less than two weeks prior to first dose of
             study medication and have not recovered from all acute toxicities from prior
             treatments.

          -  Have participated in any clinical trial involving conventional or investigational
             drugs within 28 days prior to initiation of ENMD-2076 dosing.

          -  Have active, acute, or chronic clinically significant infections.

          -  Have uncontrolled severe hypertension or congestive heart failure.

          -  Have active angina pectoris or recent myocardial infarction (within 6 months).

          -  Have chronic atrial fibrillation or QTc of greater than 470 msec.

          -  Have had major surgery within 21 days of starting therapy.

          -  Have planned surgical treatment of tumor(s)

          -  Have additional uncontrolled serious medical or psychiatric illness.

          -  Have any medical condition that would impair the administration of oral agents
             including significant bowel resection, inflammatory bowel disease or uncontrolled
             nausea or vomiting.

          -  Have a 2+ protein by urinalysis or a history of nephrotic syndrome.

          -  Known central nervous system metastasis.

          -  Have history of deep vein thrombosis or pulmonary embolus, unless they are receiving
             therapeutic anticoagulation with warfarin or low-molecular-weight heparin.